Log in with your email address username.


[Correspondence] Outcomes in the EXAMINATION trial – Authors’ reply

The rationale and design of the EXAMINATION trial,1 reported the primary and the secondary endpoints to be assessed at 1 year2 and every year up to 5 year follow-up.3 These endpoints were selected following Academic Research Consortium (ARC) guidelines, which specifically recommend that trials of drug-eluting stent select and concomitantly report both patient-oriented and stent-oriented (or device-oriented) endpoints.4 Individual components of these two endpoints were also prespecified and reported in the design paper.